Solid Biosciences Inc.
Solid Biosciences Inc. (SLDB): 10 pipeline candidates · 1 upcoming catalyst · ~24 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
24.3 months
D/E 0.13 · 12% dilution
Lead: Phase 3
10 candidates
1 upcoming, next in ~2754d
0 buys · 23 sells (180d)
A transparent, data-derived signal for Solid Biosciences Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$738.4M
Cash
$298.4M
Quarterly Burn
$47.2M
Runway
24.3 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (10 candidates)
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
139
Total value held
$676.1M
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 23,813,292 | $171.5M |
| ra capital management, l.p. | 9,339,978 | $67.2M |
| janus henderson group plc | 8,021,390 | $57.8M |
| blackrock, inc. | 4,958,354 | $35.7M |
| fmr llc | 3,606,404 | $26.0M |
| deep track capital, lp | 3,565,062 | $25.7M |
| armistice capital, llc | 3,200,000 | $23.0M |
| vanguard capital management llc | 2,674,624 | $19.3M |
| citadel advisors llc | 2,648,200 | $19.1M |
| ameriprise financial inc | 2,438,849 | $17.6M |
Showing top 10 of 139 institutional holders of Solid Biosciences Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Solid Biosciences Inc.'s pipeline?
Solid Biosciences Inc. (SLDB) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Solid Biosciences Inc.'s lead drug candidate?
Solid Biosciences Inc.'s most advanced tracked candidate is AVB-202-TT (Preclinical) for Friedreich's ataxia.
What is Solid Biosciences Inc.'s next catalyst?
Solid Biosciences Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effica" — expected January 1, 2034.
What is Solid Biosciences Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Solid Biosciences Inc. has approximately 24.3 months of cash runway.
What is Solid Biosciences Inc.'s market capitalization?
Solid Biosciences Inc.'s market capitalization is approximately $738.4M.
Get the full picture on Solid Biosciences Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.